Objective: To assess the efficacy of golimumab (GLM) in refractory uveitis associated to spondyloarthritis (SpA).
INTRODUCTION
The term spondyloarthritis (SpA) encompasses a group of chronic inflammatory diseases characterized by joint involvement and extra-articular manifestations strongly associated with HLA B27 antigen (1-4). It includes reactive arthritis (formerly called Reiter syndrome), ankylosing spondylitis (AS), inflammatory bowel disease (Crohn"s disease and ulcerative colitis), undifferentiated SpA and psoriatic arthritis (PsA) (1-4).
Uveitis, the most common extra-articular manifestation of SpA (5,6), has been included in the recently proposed classification criteria for axial and peripheral SpA (7,8). The most frequent pattern of ocular involvement in SpA is a recurrent acute unilateral anterior uveitis, which usually resolves with topical therapy (9,10). In some cases, however, uveitis may be refractory or relapsing, and treatment with an additional conventional immunosuppressive agents (mainly sulfasalazine or methotrexate) may be required (9,11-13).
Despite using topical and conventional immunosuppressive agents, uveitis sometimes becomes chronic or relapsing leading to major ocular sequelae. According to published data, up to one-third of patients experience substantial visual impairment and up to Although IFX or ADA are the first-line recommended monoclonal antibodies for the management of SpA-uveitis refractory to conventional drugs, in some cases inadequate response, due to either intolerance or inefficacy, may be observed following the use of these two biologic agents. These patients represent a major challenge for the clinician, since no well-establish approach has been suggested to deal with these cases. To provide an alternative therapeutic option in refractory SpA-related uveitis, we have used Golimumab (GLM), a novel fully humanized anti-TNF-α monoclonal antibody that has been approved for the treatment of rheumatoid arthritis, PsA, AS and ulcerative colitis (22-24). Compared to IFX, GLM is administered by subcutaneous route and has a lower risk for developing neutralizing antibodies. Moreover, it has potential advantages over ADA, as its monthly administration. However, the few published studies on the efficacy of GLM in refractory uveitis are based on small case series (25) or heterogeneous subgroups of patients with this disorder (26-32).
Taking into account all these considerations, we conducted a multicenter study to analyze the clinical response to GLM in patients diagnosed with SpA-related uveitis refractory to other systemic immunosuppressive agents.
PATIENTS AND METHODS
This is an open-label, multicenter study including 15 patients with SpA-related uveitis.
All of them had been refractory to previous standard synthetic immunosuppressive drugs and in some cases to at least one anti-TNF-α agent.
Working definitions
SpA was diagnosed according to the proposed classification criteria for axial or peripheral SpA (8). The diagnosis of AS was made following the modified New York criteria (33) and that of PsA according to the Classification criteria for Psoriatic Arthritis (CASPAR) (34).
Refractory uveitis was defined when the patient did not achieve clinical remission despite of the use of standard synthetic immunosuppressive drugs and/or anti-TNF-α agents or whether the treatment with these drugs was not sufficient to reach disease remission (26, 35-37).
Uveitis was classified anatomically, according to the International Uveitis Study Group (IUSG) classification (38). The degree of intraocular inflammation was evaluated according to "The Standardization of Uveitis Nomenclature (SUN) Working Group" (39). Nussenblat scale was used to evaluate the degree of vitritis (40). Macular thickness was measured by optical coherence tomography (OCT). Macular thickening was defined as a macular thickness greater than 250 μm whereas cystoid macular edema (CME) was defined as a macular thickness greater than 300 μm. The bestcorrected visual acuity (BCVA) was determined using the Snellen test.
GLM protocol
GLM was given subcutaneously at the dose of 50 mg monthly. Before GLM onset, evidence of malignancy or systemic infection, including hepatitis B or hepatitis C infection, were excluded. According to the Spanish National Guidelines, in all patients receiving anti-TNF-α drugs, latent tuberculosis was excluded by a tuberculin skin testing (PPD) and/or quantiferon and chest radiograph. Patients with latent tuberculosis received prophylaxis with isoniazid at least 4 weeks before the onset of the biologic agent. Overall, prophylaxis was maintained for 9 months. Since GLM is an off-label indication for uveitis, written informed consent was obtained from all the patients.
Statistical analysis
Clinical and laboratory variables were collected by each investigator following a protocol agreed beforehand. Categorical variables were expressed as percentages.
Continuous variables were expressed as mean±SD or as median [25th-75th
interquartile range (IQR)] as appropriate, and compared by using the Wilcoxon signedrank test. Snellen visual acuities were converted to logarithm of the minimum angle of resolution (logMAR) scores for statistical analysis.
Intraocular inflammation, macular thickness, BCVA, and sparing corticosteroid effect were the outcome variables. These variables were recorded in most patients at baseline and at 1 week, 2 weeks, 1 month, 3 months, 6 months and 1 and 2 years.
Statistical analysis was performed using the STATISTICA software (StatSoft Inc. Tulsa, Oklahoma, USA).
RESULTS

Baseline features
Fifteen patients (18 affected eyes) with SpA-related uveitis who were treated with GLM were assessed. The main baseline characteristics of this series of patients are summarized in the Table 1 . As expected, most patients were young men (n=13; 86.7%; mean age 39±6 years; median (range) age 39 (31-48) years, and HLA-B27 was positive in 11 cases. The most frequent underlying SpA subtype was AS (n=8) followed by PsA (n=6) and non-radiographic axial SpA (n=1).
The most common synthetic therapy given before GLM were methotrexate (n= 13) and sulfasalazine (n=6). Four patients had received pulses of methylprednisolone. Other drugs given before GLM onset were azathioprine (n=3), leflunomide (n=2), cyclosporine (n=1). It is worth noting that 10 of these 15 patients had also been treated with TNF-α blockers; etanercept (n=7), adalimumab (n=7), infliximab (n=6), and certolizumab (n=1). The drugs given to each patient before the onset of GLM therapy are shown in Table 1 .
Uveitis had been relapsing in 8 cases and chronic the other 7 cases. At GLM onset, all the patients showed active uveitis with cells in anterior chamber. Vitritis was seen in 4 cases, and CME and retinal vasculitis in 3 and 1 patient, respectively. In addition, at the time of GLM onset some patients already had visual sequelae: cataracts (n=3), cataracts and persistent CME (n=1), synechiae (n=5) and glaucoma (n=4). Besides ocular involvement, 8 patients also had active rheumatic disease. LFN in 2, and AZA in 1 case). As described before, the standard GLM regimen was 50 mg/sc every 4 weeks. However, the dose had to be increased to 100 mg/sc every 4 weeks in 1patient due to a new outbreak of uveitis after 4 months of GLM therapy. 
Outcome variables
Other clinical findings and side-effects following GLM therapy
We have also observed a decrease, albeit non-significant, in the frequency of uveitis outbreaks that fell from 5 [3] [4] [5] [6] outbreaks/year before GLM onset to 0.5 [0-3.5] outbreaks/year following GLM therapy (p=0.08).
Interestingly, a corticosteroid sparing effect was also observed at 2 years (Figure 4) .
Thus, the mean daily dose of prednisone was reduced from 34.4±19.4 mg at baseline to 9.2±7.3 mg at 2 years (p=0.04).
After a median follow-up of 23±7 months, 13 patients achieved complete clinical remission. In one case, in which remission was not achieved after 26 months of treatment with GLM, this agent was withdrawn, and ADA was started with good response after 14 months of therapy. In another patient, who was in clinical remission, GLM was discontinued after 36 months of treatment because he was diagnosed with a renal adenocarcinoma. He was switched to 20 mg/day remaining asymptomatic of the uveitis since them.
Regarding the safety profile of GLM, we have observed a local injection-site reaction in 1 case, a mild facial herpes zoster which evolved favorably with oral antiviral therapy and the above mentioned case of renal adenocarcinoma.
DISCUSSION
Herein, we report on 15 patients with SpA-related uveitis refractory to synthetic conventional immunosuppressive drugs, 10 of them also refractory to anti-TNF-α agents. Most of them achieved response to GLM therapy.
Uveitis prevalence in SpA ranges from 10 to 50% depending on the selected study (6, 41), the subtype of SpA (it is higher in AS and lower in undifferentiated SpA) (6), and HLA-B27 positivity (ranging between 40-48% in HLA-B27 positive and 15-25% in HLA-
B27 negative patients). (42-44).
The typical pattern in SpA-related uveitis is a unilateral, recurrent, and acute anterior involvement (45). However, there are differences in the ocular pattern depending on the subtype of SpA. Thus, uveitis in AS is usually acute, unilateral and of sudden onset.
In contrast, uveitis in PsA tends to be chronic, bilateral and with insidious onset (46-
49).
The prognosis of anterior uveitis is favourable in most patients. However, in some cases, especially in HLA-B27-postive patients, uveitis has less favourable outcome, and fibrin deposits in the anterior chamber, hypopyon, recurrences and sequelae, including CME, papillitis, cataracts, glaucoma, synechiae and severe vitritis, may be seen, leading to legal blindness or severe visual impairment in 10% of the patients (14,15,50-52 ).
Concerning to therapy, SpA-related anterior uveitis is usually treated successfully with topical therapy that includes corticosteroids and often a dilating drop to prevent posterior synechiae and to reduce spasm of the ciliary muscle. Severe unilateral disease with a sudden onset may require locally injected corticosteroids or a brief course of oral prednisone. When uveitis is bilateral, relapsing or more severe, additional immunosuppressive therapy, mainly sulfasalazine and MTX, may be needed to achieve adequate control the disease (9, 11-13, 46) .
In some patients, uveitis is refractory to these synthetic drugs, and some evidence suggests that anti-TNF-α monoclonal antibodies are more effective than the TNF cases (16, 18) .
Regrettably, a problem arises when refractory SpA-related uveitis has inadequate response to ADA or IFX therapy. In these cases, there is no well-established therapeutic protocol to be followed. Certolizumab has been suggested to be an effective agent to reduce frequency of SpA-related uveitis relapses, although data are scarce yet (62). On the other hand, GLM is a novel fully humanized anti-TNF-α monoclonal antibody approved to treat rheumatoid arthritis, PsA, AS and ulcerative colitis (22, 23, 63-65) . GLM has been reported to be as a safe agent in these conditions with a side-effect profile similar to other commercially available anti-TNF-α drugs (22, 66). Compared with the most commonly used anti-TNFα drugs, GLM has advantages in the route and periodicity of administration. Moreover, GLM is a fully human monoclonal antibody. This fact may potentially reduce the risk to develop neutralizing antibodies and allergic reactions (29-32).
There are several reports that highlight the effectiveness of GLM in immune-mediated uveitis. However, information on the efficacy of GLM in refractory SpA-related uveitis is scarce (8, 27-32) . Our results indicate that GLM may be an effective therapy for SpArelated uveitis refractory to immunosuppressive drugs, also including in some cases other anti-TNF-α biologic agents. Moreover, besides its efficacy to maintain intraocular inflammation remission, our results suggest that GLM may be useful to prevent further relapses in SpA patients with recurrent episodes of uveitis. In this regard, our data are in keeping with the scarce published results reported in heterogeneous groups of patients with uveitis that only included a few patients with SpA (26, 27, 29) . Moreover, our multicenter open-label study represents the largest series published on refractory SpA-related uveitis.
With respect to adverse side effects, although in our study we observed a case of renal carcinoma, there are many studies showing that there is no increased risk of tumors in patients treated with anti-TNF-α drugs. Therefore, it is possible that the occurrence of renal cancer in this case might have been an incidental finding unrelated to GLM (67).
CONCLUSION
In conclusion, our results indicate that GLM may be a useful therapeutic option in refractory SpA-related uveitis.
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